Mass-Action Law Dynamics Theory and Algorithm for Translational and Precision Medicine Informatics

Mass-Action Law Dynamics Theory and Algorithm for Translational and Precision Medicine Informatics? provides a comprehensive overview and update of the mass-action law-based unified dose-effect biodynamics, pharmacodynamics, bioinformatics, and the combination index theorem for synergy definition (MAL-BD/PD/BI/CI). Contents advocate the fundamental MAL-PD/BI/CI/BI principle for biomedical R&D, clinical trials protocol design computerized data analysis, illustrates the MAL-dynamics theory with sample analysis, and includes data entry and automated computer report print-outs. In 11 sections Mass-Action Law Dynamics Theory and Algorithm for Translational and Precision Medicine Informatics? leads the reader from an introduction and overview, to trial protocols and MAL-PD/CI approach for biomedical R&D in vitro and in animals. It describes the current Landscape of International FDA Drug Evaluation, Clinical Pharmacology, and Clinical Trials Guidance. This is a valuable resource for biomedical researchers, healthcare professionals, and students seeking to harness the power of data informatics in precision medicine. . gives insight into that index equation (DRIE) that digitally determines how many folds of dose-reduction is needed for each drug in synergistic combinations . provides a comprehensive overview and update of mass-action law-based unified bioinformatics, dose effect biodynamics, pharmacodynamics, and the combination index theorem for synergy definition (MAL-BD/PD/BI/CI) . describes how the MAL theory/algorithm-based Top-Down? digital approach is the opposite and yet is a complementary alternative to the observation/statistics-based Bottom-Up? traditional approach in R&D INDICE: 1. A new alternative concept for cost-effective R&D: The MALdynamics/algorithms/digital informatics2. General dynamics principle for experimental design of all dose-effect analysis and computer simulation3. MAL-PD/CI approach for biomedical R&D in vitro and in animals4. Implementation for MAL-PD Econo-Green R&D5. Digital R&D approach to international FDA drug evaluation, clinical pharmacology, and clinical trial guidance6. The epothilone story: Experimental success and clinical failure7. MAL-PD Advocacy: Public hearing, public comments and scientific recommendations8. Consensus for international FDAs on definitions of “MAL-PD” and “Synergism”9. Historical, philosophical, and mathematical analysis: Why the MAL-PD approach and the traditional approach are opposite yet complementary10. Multidisciplinary examples of applications: Papers using the MAL-PD/BD/CI/BI theory/method11. Concluding remarks

• ISBN: 978-0-443-28874-6
• Editorial: Academic Press
• Encuadernacion: Rústica
• Páginas: 438
• Fecha Publicación: 10/04/2024
• Nº Volúmenes: 1
• Idioma: Inglés